Lineage Cell Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
AMEX
Lineage Cell Therapeutics, Inc. has updated its 2025 Annual Meeting proxy statement to reflect the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, succeeding Moss Adams LLP due to a merger.
AMEX
Lineage Cell Therapeutics will hold its annual shareholder meeting on June 26, 2025, to vote on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.
AMEX
Lineage Cell Therapeutics is holding its 2025 annual meeting to elect directors, ratify the auditor, approve executive compensation, and amend the equity incentive plan.
AMEX
Lineage Cell Therapeutics is holding a special shareholder meeting to approve the issuance of common shares and warrants to Broadwood Partners, aiming to raise approximately $6 million.
AMEX
Lineage Cell Therapeutics will hold its annual shareholder meeting on June 11, 2024, to elect directors, ratify the appointment of its accounting firm, and approve executive compensation.
AMEX
Lineage Cell Therapeutics is holding its annual shareholder meeting on June 11, 2024, to vote on the election of directors, ratification of auditors, and executive compensation.